The Colitis drugs in development market research report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Colitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Colitis and features dormant and discontinued products.

GlobalData tracks 44 drugs in development for Colitis by 41 companies/universities/institutes. The top development phase for Colitis is preclinical with 36 drugs in that stage. The Colitis pipeline has 37 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Colitis pipeline products market are: Protheragen, Servatus and Privo Technologies.

The key targets in the Colitis pipeline products market include Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).

The key mechanisms of action in the Colitis pipeline product include Interleukin 23 Receptor (IL23R) Antagonist with two drugs in Preclinical. The Colitis pipeline products include eight routes of administration with the top ROA being Oral and nine key molecule types in the Colitis pipeline products market including Small Molecule, and Biologic.

Colitis overview

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections with a virus or parasite or bacterial food poisoning; inflammatory disorders, namelsy ulcerative colitis and Crohn’s disease; lack of blood flow (ischemic colitis); or past radiation exposure to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea, and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

For a complete picture of Colitis’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.